TPST-2003: dual CD19/BCMA CAR-T program (GlobeNewswire) - Nov 19, 2025 - "Phase 1 complete in patients with relapsed multiple myeloma ('rrMM'), with data expected in 2026 and a biologics license application ('BLA') in China planned for 2027;Phase 1 currently enrolling patients with POEMs syndrome, with data expected in 2027 and a BLA in China planned for 2028; Tempest will have global rights to TPST-2003 outside of China, India, Turkey and Russia, and plans to pursue a potential registrational study in rrMM in the U.S. starting in 2027; Data from Chinese pivotal study expected to validate probability of success for Tempest program, and rights will include the right to reference data generated in support of the planned China BLA."
China filing • Clinical data • New trial • Trial completion • Hematological Disorders • Multiple Myeloma
|